{'fraction_non_alphanumeric': 0.030800821355236138, 'fraction_numerical': 0.018480492813141684, 'mean_word_length': 6.169117647058823, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation of the antibiotic resistance of Pseudomonas aeruginosa isolates according to the changing guidelines

Pseudomonas aeruginosa is a Gram‐negative opportunistic pathogen that commonly found in nature.[1] Resistance to antibiotics and disinfectants is a problem in healthcare settings[2] some regulations are made in susceptibility testing and interpretation of results. Clinical and Laboratory Standards Institute (CLSI) guideline changed the minimum inhibitory concentrations (MICs) of piperacillin, piperacillin tazobactam, imipenem and meropenem which are used in the treatment of Pseudomonas infections, in 2012.[3] The aim of this study was; evaluating MIC values of P. aeruginosa isolates which were isolated from clinical specimens according to the CLSI 2011.[4] CLSI 2012[3] and European Committee on Antimicrobial Susceptibility Testing (EUCAST)[5] guidelines, to reveal differences in susceptibility rates and to contribute to the debate on guide exchange.